Wilson Therapeutics Progressing Its Copper Modulating Agent To Phase III

Bolstered by positive top-line Phase II trial data, Sweden-based Wilson Therapeutics will independently progress its copper modulating agent and lead asset into Phase III trials next year for the rare genetic condition known as Wilson's Disease.

Wilson's disease

Swedish biopharma Wilson Therapeutics AB has been talking to regulatory bodies and is now drafting plans to advance its lead asset WTX101 into Phase III next year after a Phase II trial met its primary endpoint treating patients with the condition known as Wilson's Disease.

An inherited disorder characterized by too much copper in the liver, brain and other tissues, Wilson's Disease can prove fatal...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip